Početna stranicaEVGN • NASDAQ
add
Evogene Ltd
Preth. zaklj. cijena
1,67 $
Dnevni raspon
1,59 $ - 1,66 $
Godišnji raspon
1,44 $ - 10,40 $
Tržišna kapitalizacija
7,95 mil. USD
Prosječna količina
559,55 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Prihod | 1,80 mil. | −52,32 % |
Operativni troškovi | 8,17 mil. | 9,83 % |
Neto dohodak | −7,63 mil. | −91,52 % |
Neto profitabilnost | −424,83 | −301,69 % |
Zarada po dionici | −1,31 | −63,75 % |
EBITDA | −6,83 mil. | −93,87 % |
Efektivna porezna stopa | −0,01 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 19,95 mil. | −46,40 % |
Ukupna imovina | 40,11 mil. | −30,53 % |
Ukupne obveze | 27,88 mil. | 27,39 % |
Ukupni kapital | 12,24 mil. | — |
Dionice u optjecaju | 6,79 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | −2,61 | — |
Povrat imovine | −45,97 % | — |
Povrat kapitala | −110,69 % | — |
Tok novca
Neto promjena novca
(USD) | ruj 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | −7,63 mil. | −91,52 % |
Gotovina od poslovanja | −4,93 mil. | −14,15 % |
Gotovina iz ulaganja | 2,02 mil. | −44,68 % |
Gotovina iz financiranja | 4,73 mil. | −39,30 % |
Neto promjena novca | 1,83 mil. | −74,18 % |
Slobodan tok novca | 757,88 tis. | 124,92 % |
Više
Evogene is a computational biology company based in Israel. Evogene Ltd. has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence, while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF, Bayer, Corteva, ICL Group Ltd. as well as various academic and medical institutions. Wikipedia
Glavni izvršni direktor
Osnovano
2002
Web-lokacija
Zaposlenici
142